Related Experiment Video

Updated: May 19, 2026

Effect of Hyaluronic Acid 35 kDa on an In Vitro Model of Preterm Small Intestinal Injury and Healing Using Enteroid-Derived Monolayers
09:36

Effect of Hyaluronic Acid 35 kDa on an In Vitro Model of Preterm Small Intestinal Injury and Healing Using Enteroid-Derived Monolayers

Published on: July 28, 2022

Impact of hydroxyurea on clinical events in the BABY HUG trial

Courtney D Thornburg1, Beatrice A Files, Zhaoyu Luo

  • 1Department of Pediatrics, Duke University Medical Center, Durham, NC 27710, USA. courtney.thornburg@dm.duke.edu

Blood
|August 24, 2012
PubMed

Insights

Hydroxyurea significantly reduced pain, acute chest syndrome, and hospitalizations in infants with sickle cell anemia. This treatment is safe and effective for young children with this condition.

Area of Science:

  • Pediatric Hematology
  • Clinical Pharmacology
  • Sickle Cell Disease Research

Background:

  • Sickle cell anemia (SCA) is a serious genetic blood disorder.
  • Early intervention in SCA can improve long-term outcomes.
  • Hydroxyurea is a medication used to manage SCA in older children and adults.

Purpose of the Study:

  • To evaluate the efficacy and safety of hydroxyurea in infants with SCA.
  • To compare clinical events in infants treated with hydroxyurea versus placebo.
  • To provide data for clinicians on hydroxyurea use in very young SCA patients.

Main Methods:

  • Phase 3, multicenter, randomized, double-blind, placebo-controlled trial (BABY HUG).
  • 193 infants (9-18 months) with SCA randomized to hydroxyurea (20 mg/kg/d) or placebo.
  • 374 patient-years of follow-up, monitoring clinical events and safety.

Main Results:

  • Hydroxyurea significantly reduced rates of pain, dactylitis, acute chest syndrome, and hospitalizations.
  • Even asymptomatic infants showed fewer hospitalizations and transfusions with hydroxyurea.
  • Mild myelosuppression observed, but no increased risk of bacteremia or serious infections.

Conclusions:

  • Hydroxyurea is safe and effective for treating infants with sickle cell anemia.
  • Early hydroxyurea treatment can prevent serious clinical events in young children with SCA.
  • These findings support hydroxyurea as a therapeutic option for infants with SCA.

More Related Videos

Modeling Posthemorrhagic Hydrocephalus of Prematurity in Rats04:12

Modeling Posthemorrhagic Hydrocephalus of Prematurity in Rats

Published on: March 28, 2025

Related Concept Videos

Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...